Lundbeck increases its share capital by 11,204 shares (0.006% of outstanding shares) as a result of employee warrant exercise
H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 56,020, as a consequence of the exercise of employee warrants.
The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 6,868 shares at DKK 97 and 4,336 shares at DKK 102. Proceeds to the company are DKK 1,108,468 (approximately USD 198,387). The increase corresponds to approximately 0,006% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2013. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Commerce and Companies Agency. Lundbeck's current share capital amounts to DKK 980,731,415 and will after the capital increase be DKK 980,787,435. The capital increase is expected to be finalized shortly.
|Palle Holm Olesen||Mads Kronborg|
|Chief Specialist, Head of Investor Relations||Media Relations Manager|
|+45 36 43 24 26||+45 36 43 28 51|
|Investor Relations Officer|
|+45 36 43 33 86|
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today, Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with brain disorders. In 2012, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.